{"id":9127,"date":"2018-12-06T11:15:00","date_gmt":"2018-12-06T10:15:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/"},"modified":"2026-05-05T22:12:14","modified_gmt":"2026-05-05T20:12:14","slug":"natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","title":{"rendered":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790"},"content":{"rendered":"
IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson\u2019s Disease utgiven av Nature.<\/strong><\/div>\n

IRL790 \u00e4r en av IRLAB:s ledande l\u00e4kemedelskandidater och utvecklas f\u00f6r behandling av dyskinesier och psykos vid Parkinsons sjukdom. Den kliniska Fas Ib-studien visar att IRL790 \u00e4r v\u00e4l tolererad och har en mycket god s\u00e4kerhetsprofil. Vidare visades den positiva effekten att dyskinesier minskade i gruppen behandlad med IRL790, men inte i placebogruppen. L\u00e4kemedelskandidaten genomg\u00e5r nu en klinisk Fas IIa-studie i en st\u00f6rre grupp patienter f\u00f6r vidare studier av den effekt som observerades i Fas Ib-studien.<\/span><\/p>\n

\u201dAtt v\u00e5r studie nu blir publicerad i tidskriften npj Parkinson\u2019s Disease<\/em> validerar v\u00e5r forskning och \u00e4r sj\u00e4lvklart en stor merit f\u00f6r IRLAB, v\u00e5ra samarbetspartners och studiens pr\u00f6vningsledare\u201d, sade Joakim Tedroff, medicinsk chef (CMO) p\u00e5 IRLAB.<\/span><\/p>\n

npj Parkinson\u2019s Disease <\/span><\/em>publiceras av Nature<\/em> och \u00e4r en internationell tidskrift som lyfter fram de viktigaste vetenskapliga framstegen inom forskning om Parkinsons sjukdom.<\/span><\/p>\n

Publikationen: Svenningsson, P. et al<\/em>. <\/span>Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia\u2014a phase 1b trial. npj Parkinson\u2019s Disease<\/em>. DOI-nummer 10.1038\/s41531-018-0071-3.<\/span><\/p>\n

L\u00e4nk till npj Parkinson\u2019s Diesease: www.nature.com\/npjparkd\/<\/a><\/p>\n

\n

F\u00f6r mer information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n

Joakim Tedroff, CMO\u00a0
Tel: +46 70\u00a0760 16 91
E-post: joakim.tedroff@irlab.se<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien
\nmed IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i
\nden ansedda vetenskapliga tidskriften npj Parkinson\u2019s Disease utgiven av Nature.<\/p>\n","protected":false},"template":"","class_list":["post-9127","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNatures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson\u2019s Disease utgiven av Nature.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T20:12:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\",\"name\":\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2018-12-06T10:15:00+00:00\",\"dateModified\":\"2026-05-05T20:12:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","og_locale":"sv_SE","og_type":"article","og_title":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","og_description":"IRLAB meddelade idag att en publikation baserad p\u00e5 den kliniska Fas Ib-studien med IRL790 i patienter med Parkinsons sjukdom och dyskinesier idag publicerats i den ansedda vetenskapliga tidskriften npj Parkinson\u2019s Disease utgiven av Nature.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","og_site_name":"IRLAB","article_modified_time":"2026-05-05T20:12:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/","name":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2018-12-06T10:15:00+00:00","dateModified":"2026-05-05T20:12:14+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/natures-npj-parkinsons-disease-publicerar-klinisk-studie-med-irlabs-lakemedelskandidat-irl790\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"Natures npj Parkinson\u2019s Disease publicerar klinisk studie med IRLAB:s l\u00e4kemedelskandidat IRL790"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}